Ji-Fan Hu

List of Publications by Year
in descending order

120 papers	5,562 citations	71102 41 h-index	88630 70 g-index
122 all docs	122 docs citations	122 times ranked	7370 citing authors

#	Article	IF	Citations
1	Pluripotency exit is guided by the Peln1-mediated disruption of intrachromosomal architecture. Journal of Cell Biology, 2022, 221, .	5.2	3
2	Nuclear-Encoded lncRNA MALAT1 Epigenetically Controls Metabolic Reprogramming in HCC Cells through the Mitophagy Pathway. Molecular Therapy - Nucleic Acids, 2021, 23, 264-276.	5.1	61
3	Long noncoding RNA: A resident staff of genomic instability regulation in tumorigenesis. Cancer Letters, 2021, 503, 103-109.	7.2	12
4	Chromatin lncRNA Platr10 controls stem cell pluripotency by coordinating an intrachromosomal regulatory network. Genome Biology, 2021, 22, 233.	8.8	12
5	The Nucleus/Mitochondria-Shuttling LncRNAs Function as New Epigenetic Regulators of Mitophagy in Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 699621.	3.7	7
6	Genome-wide interaction target profiling reveals a novel Peblr20-eRNA activation pathway to control stem cell pluripotency. Theranostics, 2020, 10, 353-370.	10.0	23
7	JMJD3 acts in tandem with KLF4 to facilitate reprogramming to pluripotency. Nature Communications, 2020, 11, 5061.	12.8	24
8	Osblr8 orchestrates intrachromosomal loop structure required for maintaining stem cell pluripotency. International Journal of Biological Sciences, 2020, 16, 1861-1875.	6.4	6
9	Oplr16 serves as a novel chromatin factor to control stem cell fate by modulating pluripotency-specific chromosomal looping and TET2-mediated DNA demethylation. Nucleic Acids Research, 2020, 48, 3935-3948.	14.5	20
10	LncRNA Functions as a New Emerging Epigenetic Factor in Determining the Fate of Stem Cells. Frontiers in Genetics, 2020, 11, 277.	2.3	65
11	Long noncoding RNAs and their epigenetic function in hematological diseases. Hematological Oncology, 2019, 37, 15-21.	1.7	11
12	Profiling the long noncoding RNA interaction network in the regulatory elements of target genes by chromatin in situ reverse transcription sequencing. Genome Research, 2019, 29, 1521-1532.	5.5	27
13	miRâ€‘338â€‘3p inhibits A549 lung cancer cell proliferation and invasion by targeting AKT and Î²â€‘catenin signaling pathways. Molecular Medicine Reports, 2019, 20, 33-40.	2.4	10
14	FLI1 Exonic Circular RNAs as a Novel Oncogenic Driver to Promote Tumor Metastasis in Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 1302-1317.	7.0	113
15	Effect of MALAT1 in the crosstalk between nucleus and mitochondria on mitochondrial reprogramming in hepatocellular carcinoma cells.. Journal of Clinical Oncology, 2019, 37, e14711-e14711.	1.6	2
16	Genome-wide target interactome profiling reveals a novel epigenetic pathway for oncogenic lncRNA in breast cancer. American Journal of Cancer Research, 2019, 9, 714-729.	1.4	19
17	Aberrant shuttling of long noncoding RNAs during the mitochondria-nuclear crosstalk in hepatocellular carcinoma cells. American Journal of Cancer Research, 2019, 9, 999-1008.	1.4	17
18	Profiling the epigenetic interplay of lncRNA RUNXOR and oncogenic RUNX1 in breast cancer cells by gene in situ cis-activation. American Journal of Cancer Research, 2019, 9, 1635-1649.	1.4	8

#	Article	IF	Citations
19	Epigenetic Targeting of Granulin in Hepatoma Cells by Synthetic CRISPR dCas9 Epi-suppressors. Molecular Therapy - Nucleic Acids, 2018, 11, 23-33.	5.1	52
20	A novel FLI1 exonic circular RNA promotes metastasis in breast cancer by coordinately regulating TET1 and DNMT1. Genome Biology, 2018, 19, 218.	8.8	292
21	Mitochondrial peptides modulate mitochondrial function during cellular senescence. Aging, 2018, 10, 1239-1256.	3.1	98
22	The effects of mitochondria-associated long noncoding RNAs in cancer mitochondria: New players in an old arena. Critical Reviews in Oncology/Hematology, 2018, 131, 76-82.	4.4	51
23	Cytokine IL9 Triggers the Pathogenesis of Inflammatory Bowel Disease Through the miR21-CLDN8 Pathway. Inflammatory Bowel Diseases, 2018, 24, 2211-2223.	1.9	16
24	Targeting the IGF1R Pathway in Breast Cancer Using Antisense lncRNA-Mediated Promoter cis Competition. Molecular Therapy - Nucleic Acids, 2018, 12, 105-117.	5.1	33
25	Combined RNA-seq and RAT-seq mapping of long noncoding RNAs in pluripotent reprogramming. Scientific Data, 2018, 5, 180255.	5.3	17
26	FLI1 circular RNA as biomarkers for tracking disease progression and as potential therapeutic targets in small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, e20573-e20573.	1.6	0
27	Targeting Jurkat T Lymphocyte Leukemia Cells by an Engineered Interferon-Alpha Hybrid Molecule. Cellular Physiology and Biochemistry, 2017, 42, 519-529.	1.6	8
28	Manipulation of nuclear architecture through CRISPR-mediated chromosomal looping. Nature Communications, 2017, 8, 15993.	12.8	224
29	Targeted breast cancer therapy by harnessing the inherent blood group antigen immune system. Oncotarget, 2017, 8, 15034-15046.	1.8	7
30	Mitochondrial DNA Hypomethylation Is a Biomarker Associated with Induced Senescence in Human Fetal Heart Mesenchymal Stem Cells. Stem Cells International, 2017, 2017, 1-12.	2.5	32
31	Long noncoding RNAs coordinate functions between mitochondria and the nucleus. Epigenetics and Chromatin, 2017, 10, 41.	3.9	86
32	CRISPR Cas9-guided chromatin immunoprecipitation identifies miR483 as an epigenetic modulator ofIGF2imprinting in tumors. Oncotarget, 2017, 8, 34177-34190.	1.8	23
33	Systematic Correlation Analyses of Circulating Tumor Cells with Clinical Variables and Tumor Markers in Lung Cancer Patients. Journal of Cancer, 2017, 8, 3099-3104.	2.5	17
34	Knockdown of COPS3 Inhibits Lung Cancer Tumor Growth in Nude Mice by Blocking Cell Cycle Progression. Journal of Cancer, 2017, 8, 1129-1136.	2.5	9
35	Friend leukemia virus integration 1 promotes tumorigenesis of small cell lung cancer cells by activating the miR-17-92 pathway. Oncotarget, 2017, 8, 41975-41987.	1.8	21
36	Effect of friend leukemia virus integration 1 on tumorigenesis of small cell lung cancer cells and activation of the miR-17-92 pathway.. Journal of Clinical Oncology, 2017, 35, e20015-e20015.	1.6	0

#	Article	IF	Citations
37	Loss of insulin-like growth factor II imprinting is a hallmark associated with enhanced chemo/radiotherapy resistance in cancer stem cells. Oncotarget, 2016, 7, 51349-51364.	1.8	24
38	Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients. Journal of Immunology Research, 2016, 2016, 1-8.	2.2	7
39	Therapeutic Potential of HGF-Expressing Human Umbilical Cord Mesenchymal Stem Cells in Mice with Acute Liver Failure. International Journal of Hepatology, 2016, 2016, 1-13.	1.1	28
40	Combining Telomerase Reverse Transcriptase Genetic Variant rs2736100 with Epidemiologic Factors in the Prediction of Lung Cancer Susceptibility. Journal of Cancer, 2016, 7, 846-853.	2.5	14
41	Converting Skin Fibroblasts into Hepatic-like Cells by Transient Programming. Journal of Cellular Biochemistry, 2016, 117, 589-598.	2.6	5
42	Valproic Acid Enhances iPSC Induction From Human Bone Marrow-Derived Cells Through the Suppression of Reprogramming-Induced Senescence. Journal of Cellular Physiology, 2016, 231, 1719-1727.	4.1	28
43	Evaluation of Circulating Tumor Cells in Predicting Therapeutic Response in Small Cell Lung Cancer Patients. Archives of Medical Research, 2016, 47, 454-459.	3.3	9
44	Pro-inflammatory miR-223 mediates the cross-talk between the IL23 pathway and the intestinal barrier in inflammatory bowel disease. Genome Biology, 2016, 17, 58.	8.8	137
45	Epigenetic suppression of the antitumor cytotoxicity of NK cells by histone deacetylase inhibitor valproic acid. American Journal of Cancer Research, 2016, 6, 600-14.	1.4	11
46	A placental growth factor-positively charged peptide potentiates the antitumor activity of interferon-gamma in human brain glioblastoma U87 cells. American Journal of Cancer Research, 2016, 6, 214-25.	1.4	2
47	Antitumor potential of a synthetic interferon-alpha/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer cells. Scientific Reports, 2015, 5, 16975.	3.3	12
48	Bioinformatics analyses of differentially expressed genes associated with bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. OncoTargets and Therapy, 2015, 8, 2681.	2.0	12
49	Combination of Circulating Tumor Cells with Serum Carcinoembryonic Antigen Enhances Clinical Prediction of Non-Small Cell Lung Cancer. PLoS ONE, 2015, 10, e0126276.	2.5	43
50	Inhibition of HIV-1 Viral Infection by an Engineered CRISPR Csy4 RNA Endoribonuclease. PLoS ONE, 2015, 10, e0141335.	2.5	4
51	Restoration of IGF2 imprinting by polycomb repressive complex 2 docking factor SUZ12 in colon cancer cells. Experimental Cell Research, 2015, 338, 214-221.	2.6	17
52	In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells. BMC Immunology, 2015, 16, 61.	2.2	41
53	Histone deacetylase inhibitor valproic acid promotes the induction of pluripotency in mouse fibroblasts by suppressing reprogramming-induced senescence stress. Experimental Cell Research, 2015, 337, 61-67.	2.6	39
54	Hematopoietic recovery of acute radiation syndrome by human superoxide dismutaseâ€“expressing umbilical cord mesenchymal stromal cells. Cytotherapy, 2015, 17, 403-417.	0.7	21

#	Article	IF	Citations
55	A Novel Inherited Mutation in PRKAR1A Abrogates PreRNA Splicing in a Carney Complex Family. Canadian Journal of Cardiology, 2015, 31, 1393-1401.	1.7	5
56	Aberrant allele-switch imprinting of a novel IGF1R intragenic antisense non-coding RNA in breast cancers. European Journal of Cancer, 2015, 51, 260-270.	2.8	35
57	Friend leukemia virus integration 1 activates the Rho GTPase pathway and is associated with metastasis in breast cancer. Oncotarget, 2015, 6, 23764-23775.	1.8	20
58	Effect of long noncoding RNA RUNXOR on the epigenetic regulation of RUNX1 in acute myelocytic leukemia.. Journal of Clinical Oncology, 2015, 33, 7018-7018.	1.6	0
59	The antitumor activity of synthetic interferon-alpha in pancreatic cancer cells.. Journal of Clinical Oncology, 2015, 33, e15272-e15272.	1.6	0
60	Long Noncoding RNA HOTAIR as an Independent Prognostic Marker in Cancer: A Meta-Analysis. PLoS ONE, 2014, 9, e105538.	2.5	58
61	A novel antisense long noncoding RNA within the IGF1R gene locus is imprinted in hematopoietic malignancies. Nucleic Acids Research, 2014, 42, 9588-9601.	14.5	130
62	Chromatin looping is needed for iPSC induction. Cell Cycle, 2014, 13, 1-2.	2.6	22
63	An intragenic long noncoding RNA interacts epigenetically with theRUNX1promoter and enhancer chromatin DNA in hematopoietic malignancies. International Journal of Cancer, 2014, 135, 2783-2794.	5.1	82
64	Promoter histone H3K27 methylation in the control of IGF2 imprinting in human tumor cell lines. Human Molecular Genetics, 2014, 23, 117-128.	2.9	40
65	Long noncoding RNA-mediated intrachromosomal interactions promote imprinting at the Kcnq1 locus. Journal of Cell Biology, 2014, 204, 61-75.	5.2	118
66	Epigenetic reprogramming reverses the malignant epigenotype of the MMP/TIMP axis genes in tumor cells. International Journal of Cancer, 2014, 134, 1583-1594.	5.1	45
67	Human umbilical cord mesenchymal stromal cells rescue mice from acetaminophen-induced acute liver failure. Cytotherapy, 2014, 16, 1207-1219.	0.7	54
68	Targeted gene suppression by inducing de novo DNA methylation in the gene promoter. Epigenetics and Chromatin, 2014, 7, 20.	3.9	17
69	Cancer Stem Cell Marker Musashi-1 rs2522137 Genotype Is Associated with an Increased Risk of Lung Cancer. PLoS ONE, 2014, 9, e95915.	2.5	7
70	Copper induces cellular senescence in human glioblastoma multiforme cells through downregulation of Bmi-1. Oncology Reports, 2013, 29, 1805-1810.	2.6	31
71	Intrachromosomal Looping Is Required for Activation of Endogenous Pluripotency Genes during Reprogramming. Cell Stem Cell, 2013, 13, 30-35.	11.1	120
72	Serum peptidomic profiling identifies a minimal residual disease detection and prognostic biomarker for patients with acute leukemia. Oncology Letters, 2013, 6, 1453-1460.	1.8	11

#	Article	IF	Citations
73	Gene therapy for cancer through adenovirus vector-mediated expression of the Ad5 early region gene 1A based on loss of IGF2 imprinting. Oncology Reports, 2013, 30, 1814-1822.	2.6	10
74	The combination of polyalanine expansion mutation and a novel missense substitution in transcription factor FOXL2 leads to different ovarian phenotypes in blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) patients. Human Reproduction, 2012, 27, 3347-3357.	0.9	12
75	Gene therapy for colorectal cancer by an oncolytic adenovirus that targets loss of the insulin-like growth factor 2 imprinting system. Molecular Cancer, 2012, 11, 86.	19.2	14
76	Therapeutic Efficacy by Targeting Correction of Notch1-Induced Aberrants in Uveal Tumors. PLoS ONE, 2012, 7, e44301.	2.5	17
77	Promotion of the induction of cell pluripotency through metabolic remodeling by thyroid hormone triiodothyronine-activated PI3K/AKT signal pathway. Biomaterials, 2012, 33, 5514-5523.	11.4	37
78	Potentiation of tumor radiotherapy by a radiationâ€inducible oncolytic and oncoapoptotic adenovirus in cervical cancer xenografts. International Journal of Cancer, 2012, 130, 443-453.	5.1	22
79	A Novel Anticancer Therapy That Simultaneously Targets Aberrant p53 and Notch Activities in Tumors. PLoS ONE, 2012, 7, e46627.	2.5	6
80	Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 1130-1137.	3.8	28
81	Putative tumor suppressor miRâ€145 inhibits colon cancer cell growth by targeting oncogene friend leukemia virus integration 1 gene. Cancer, 2011, 117, 86-95.	4.1	156
82	IGFBP-2 Enhances VEGF Gene Promoter Activity and Consequent Promotion of Angiogenesis by Neuroblastoma Cells. Endocrinology, 2011, 152, 3332-3342.	2.8	97
83	Interruption of intrachromosomal looping by CCCTC binding factor decoy proteins abrogates genomic imprinting of human insulin-like growth factor II. Journal of Cell Biology, 2011, 193, 475-487.	5.2	68
84	Targeted knockdown of Bcl2 in tumor cells using a synthetic TRAIL 3â€²â€UTR microRNA. International Journal of Cancer, 2010, 126, 2229-2239.	5.1	9
85	Transient in vitro epigenetic reprogramming of skin fibroblasts into multipotent cells. Biomaterials, 2010, 31, 2779-2787.	11.4	31
86	Inhibition of Retinoblastoma In Vitro and In Vivo with Conditionally Replicating Oncolytic Adenovirus H101. , 2010, 51, 2626.		24
87	Targeted tumor gene therapy based on loss of IGF2 imprinting. Cancer Biology and Therapy, 2010, 10, 290-298.	3.4	11
88	Induced epigenetic modifications of the promoter chromatin silence survivin and inhibit tumor growth. Biochemical and Biophysical Research Communications, 2010, 393, 592-597.	2.1	16
89	Enhanced Therapeutic Efficacy by Simultaneously Targeting Two Genetic Defects in Tumors. Molecular Therapy, 2009, 17, 57-64.	8.2	40
90	CTCF Regulates Allelic Expression of Igf2 by Orchestrating a Promoter-Polycomb Repressive Complex 2 Intrachromosomal Loop. Molecular and Cellular Biology, 2008, 28, 6473-6482.	2.3	193

#	Article	IF	Citations
91	A Complex Deoxyribonucleic Acid Looping Configuration Associated with the Silencing of the Maternal Igf2 Allele. Molecular Endocrinology, 2008, 22, 1476-1488.	3.7	44
92	Correction of aberrant imprinting of IGF2 in human tumors by nuclear transfer-induced epigenetic reprogramming. EMBO Journal, 2006, 25, 5329-5338.	7.8	37
93	CTCF Mediates Interchromosomal Colocalization Between Igf2/H19 and Wsb1/Nf1. Science, 2006, 312, 269-272.	12.6	413
94	IVF results in de novo DNA methylation and histone methylation at an Igf2-H19 imprinting epigenetic switch. Molecular Human Reproduction, 2005, 11, 631-640.	2.8	164
95	Epigenetic regulation of the taxol resistanceâ€“associated gene TRAG-3 in human tumors. Cancer Genetics and Cytogenetics, 2004, 151, 1-13.	1.0	30
96	Epigenetic regulation of Igf2/H19 imprinting at CTCF insulator binding sites. Journal of Cellular Biochemistry, 2003, 90, 1038-1055.	2.6	36
97	Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Human Molecular Genetics, 2003, 12, 535-549.	2.9	132
98	CTCF Binding at the Insulin-Like Growth Factor-II (IGF2)/H19 Imprinting Control Region Is Insufficient to Regulate IGF2/H19 Expression in Human Tissues. Endocrinology, 2003, 144, 4420-4426.	2.8	63
99	The Histone Code Regulating Expression of the Imprinted MouseIgf2rGene. Endocrinology, 2003, 144, 5658-5670.	2.8	66
100	A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. Journal of Clinical Investigation, 2003, 111, 265-273.	8.2	43
101	A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. Journal of Clinical Investigation, 2003, 111, 265-273.	8.2	77
102	A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis. Clinical Cancer Research, 2003, 9, 2719-26.	7.0	57
103	An Imprinted PEG1/MEST Antisense Expressed Predominantly in Human Testis and in Mature Spermatozoa. Journal of Biological Chemistry, 2002, 277, 13518-13527.	3.4	44
104	Examining Histone Acetylation at Specific Genomic Regions. , 2002, 181, 285-296.		4
105	Tissue-specific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development. International Journal of Cancer, 2001, 91, 644-649.	5.1	131
106	Tissue-specific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development. , 2001, 91, 644.		1
107	Tissueâ€specific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development. International Journal of Cancer, 2001, 91, 644-649.	5.1	6
108	Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium. International Journal of Cancer, 2000, 85, 330-335.	5.1	174

#	Article	IF	Citations
109	Allele-Specific Histone Acetylation Accompanies Genomic Imprinting of the Insulin-Like Growth Factor II Receptor Gene**Supported by NIH Grant DK-36054 and by the Research Service of the Department of Veterans Affairs.. Endocrinology, 2000, 141, 4428-4435.	2.8	58
110	Symmetric and Asymmetric DNA Methylation in the Human IGF2â€“H19 Imprinted Region. Genomics, 2000, 64, 132-143.	2.9	78
111	Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium. International Journal of Cancer, 2000, 85, 330.	5.1	15
112	Allele-Specific Histone Acetylation Accompanies Genomic Imprinting of the Insulin-Like Growth Factor II Receptor Gene. Endocrinology, 2000, 141, 4428-4435.	2.8	19
113	Lack of Reciprocal Genomic Imprinting of Sense and Antisense RNA of Mouse Insulin-like Growth Factor II Receptor in the Central Nervous System1. Biochemical and Biophysical Research Communications, 1999, 257, 604-608.	2.1	46
114	Dissociation of IGF2 and H19 imprinting in human brain. Brain Research, 1998, 810, 1-8.	2.2	66
115	The Role of Histone Acetylation in the Allelic Expression of the Imprinted Human Insulin-like Growth Factor II Gene. Biochemical and Biophysical Research Communications, 1998, 251, 403-408.	2.1	54
116	Tissue-Specific Imprinting of the Mouse Insulin-Like Growth Factor II Receptor Gene Correlates with Differential Allele-Specific DNA Methylation. Molecular Endocrinology, 1998, 12, 220-232.	3.7	59
117	Modulation of Igf2 Genomic Imprinting in Mice Induced by 5-Azacytidine, an Inhibitor of DNA Methylation. Molecular Endocrinology, 1997, 11, 1891-1898.	3.7	45
118	Genomic Deletion of an Imprint Maintenance Element Abolishes Imprinting of Both Insulin-like Growth Factor II andH19. Journal of Biological Chemistry, 1997, 272, 20715-20720.	3.4	40
119	Repression of hepatitis B virus (HBV) transgene and HBV-induced liver injury by low protein diet. Oncogene, 1997, 15, 2795-2801.	5.9	26
120	Promoter-specific Modulation of Insulin-like Growth Factor II Genomic Imprinting by Inhibitors of DNA Methylation. Journal of Biological Chemistry, 1996, 271, 18253-18262.	3.4	66